2006
DOI: 10.1016/j.joms.2005.10.017
|View full text |Cite
|
Sign up to set email alerts
|

Disseminated Rhinocerebral Mucormycosis: A Case Report and Review of the Literature

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

2
27
0
3

Year Published

2008
2008
2015
2015

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 47 publications
(33 citation statements)
references
References 53 publications
2
27
0
3
Order By: Relevance
“…Culturing the fungus from CSF occurs in less than 5% for Zygomycetes (12,13). Histopathological examination shows aseptate and irregular fungal hyphae branching with neutrophilic infiltrate invading the smaller blood vessels and causing necrosis (1,6,(9)(10)(11)14). We confirmed mucormycosis infection with histopathological examination in both cases.…”
Section: Discussionsupporting
confidence: 60%
See 3 more Smart Citations
“…Culturing the fungus from CSF occurs in less than 5% for Zygomycetes (12,13). Histopathological examination shows aseptate and irregular fungal hyphae branching with neutrophilic infiltrate invading the smaller blood vessels and causing necrosis (1,6,(9)(10)(11)14). We confirmed mucormycosis infection with histopathological examination in both cases.…”
Section: Discussionsupporting
confidence: 60%
“…Radiological studies such as CT or MRI show contrast enhancing masses within sinuses, cavernous sinus thrombosis, intracranial masses, brain abscesses and ischaemic infarcts in cases with mucormycosis (1,6,(9)(10)(11)14). The our first case, MRI revealed increase of soft tissues in the maxillary, sphenoid and ethmoid sinuses and contrast-enhancement of dura around the affected area and of extraocular muscles on the left side.…”
Section: Discussionmentioning
confidence: 66%
See 2 more Smart Citations
“…Amphotericin B deoxycholate (Amp B), and its lipid presentations, with less nephrotoxicity, remain the antifungals of choice for the treatment of mucormycosis (O'Neill et al, 2006;Uçkay et al, 2007). In cases of patients with mucormycosis refractory or intolerant to polyene therapy, posaconazole is considered an acceptable therapeutic option (Spellberg et al, 2009;Adegbola et al, 2009;Scheckenbach et al, 2010).…”
Section: Discussionmentioning
confidence: 99%